Summary
Evidence from several experimental systems has shown that the insulin-like growth factors (IGFs) can stimulate breast cancer proliferation. Since IGF action is mediated by interaction with specific cell surface receptors, interruption of these signalling pathways could result in inhibition of cellular growth. In all extracellular fluids, the IGFs are associated with high affinity binding proteins, the IGFBPs. Although the function of each IGFBP is not known, it is clear that under certain circumstances the IGFBPs can bind the IGFs and prevent receptor activation, and thus might have a role in a targeted approach to breast cancer therapy. Here we present our studies using IGFBP-1 to inhibit growth of the breast cancer cell line MCF-7.
Similar content being viewed by others
References
Clemmons DR: IGF binding proteins and their functions. Mol Reprod Dev 35:368–375, 1993
Nishimoto I: The IGF-II receptor system — a Gprotein-linked mechanism. Mol Reprod Dev 35: 398–407, 1993
Pessin JE, Frattali AL: Molecular dynamics of insulin/IGF-I receptor transmembrane signaling. Mol Reprod Dev 35:339–345, 1993
LeRoith D, Kavsan VM, Koval AP, Roberts CT: Phylogeny of the insulin-like growth factors (IGFs) and receptors — a molecular approach. Mol Reprod Dev 35:332–338, 1993
Daughaday WH, Rotwein P: Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev 10:68–91, 1989
Amselem S, Duquesnoy P, Attree O: Laron dwarfism and mutations of the growth hormone receptor gene. N Engl J Med 321:989–995, 1989
Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A: Mice carrying null mutations of the genes encoding insulin-like growth factor-I (Igf-1) and type-1 IGF receptor (Igflr). Cell 75:59–72, 1993
Baker J, Liu JP, Robertson EJ, Efstratiadis A: Role of insulin-like growth factors in embryonic and postnatal growth. Cell 75:73–82, 1993
Ullrich A, Gray A, Tam AW, Yang Feng T, Tsubokawa M, Collins C, Henzel W, Le Bon T, Kathuria S, Chen E, Jacobs S, Francke U, Ramachandran J, Fujita-Yamaguchi Y: Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define hormonal specificity. EMBO J 5:2503–2512, 1986
Steele-Perkins G, Turner J, Edman JC, Hari J, Pierce SB, Stover C, Rutter WJ, Roth RA: Expression and characterization of a functional human insulin-like growth factor I receptor. J Biol Chem 263:11486–11492, 1988
Russel WE, Van Wyk JJ, Pledger WJ: Inhibition of the mitogenic effects of plasma by a monoclonal antibody to somatomedin C. Proc Natl Acad Sci USA 81:2389–2391, 1984
Stiles CD, Capone GT, Scher CD, Antoniades HN, Van Wyk JJ, Pledger WJ: Dual control of cell growth by somatomedins and platelet-derived growth factor. Proc Natl Acad Sci USA 76:1279–1283, 1979
Pietrzkowski Z, Lammers R, Carpenter G, Soderquist AM, Limardo M, Phillips PD, Ullrich A, Baserga R: Constitutive expression of insulin-like growth factor 1 and insulin-like growth factor 1 receptor abrogates all requirements for exogenous growth factors. Cell Growth Diff 3:195–205, 1992
Morgan DO, Edman JC, Standring DN, Fried VA, Smith MC, Roth RA, Rutter WJ: Insulin-like growth factor II receptor as a multifunctional binding protein. Nature 329:301–307, 1987
Roth RA: Structure of the receptor for insulin-like growth factor II: the puzzle amplified. Science 239:1269–1271, 1988
Nishimoto I, Murayama Y, Katada T, Ui M, Ogata E: Possible direct linkage of insulin-like growth factor II receptor with guanine nucleotide-binding protein. J Biol Chem 264:14029–14038, 1989
Murayama Y, Okamoto T, Ogata E, Asano T, Iiri T, Katada T, Ui M, Grubb JH, Sly WS, Nishimoto I: Distinctive regulation of the functional linkage between the human cation-independent mannose 6-phosphate receptor and GTP-binding proteins by insulin-like growth factor II and mannose 6-phosphate. J Biol Chem 265:17456–17462, 1990
Treadway JL, Frattali AL, Pessin JE: Intramolecular subunit interactions between insulin and insulin-Like growth factor-1 αβ half-receptors induced by ligand and Mn/MgATP binding. Biochem 31:11801–11805, 1992
Soos MA, Field CE, Siddle K: Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity. Biochem J 290:419–426, 1993
Moxham CP, Duronio V, Jacobs S: Insulin-like growth factor I receptor β-subunit heterogeneity, evidence for hybrid tetramers composed of insulin-like growth factor I and insulin receptor heterodimers. J Biol Chem 264:13238–13244, 1989
Shimasaki S, Ling N: Identification and molecular characterization of insulin-like growth factor binding proteins (IGFBP-1, -2, -3, -4, -5, and -6). Progr Growth Factor Res 3:243–266, 1991
Jones JI, D'Ercole AJ, Camacho-Hubner C, Clemmons DR: Phosphorylation of insulin-like growth factor (IGF)-binding protein 1 in cell culture and in vivo: effects of affinity for IGF-I. Proc Natl Acad Sci USA 88:7481–7485, 1991
Jones JI, Gockerman A, Busby WH Jr, Wright G, Clemmons DR: Insulin-like growth factor binding protein-1 stimulates cell migration and binds α5β1 integrin by means of its arg-gly-asp sequence. Proc Natl Acad Sci USA 90:10553–10557, 1993
Myal Y, Shiu RPC, Bhaumick B, Bala M: Receptor binding and growth-promoting activity of insulin-like growth factors in human breast cancer cells (T-47D) in culture. Cancer Res 44:5486–5490, 1984
Yee D, Cullen KJ, Paik S, Perdue JF, Hampton B, Schwartz A, Lippman ME, Rosen N: Insulin-like growth factor II mRNA expression in human breast cancer. Cancer Res 48:6691–6696, 1988
Cullen KJ, Yee D, Sly WS, Perdue J, Hampton B, Lippman ME, Rosen N: Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res 50:48–53, 1990
Osborne CK, Coronado EB, Kitten LJ, Arteaga CL, Fuqua SAW, Ramasharma K, Marshall M, Li CH: Insulin-like growth factor II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor. Mol Endocrinol 3:1701–1709, 1989
Arteaga CL, Osborne CK: Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res 49:6237–6241, 1989
Mathieu M, Rochefort H, Barenton B, Prebois C, Vignon F: Interactions of cathepsin-D and insulin-like growth factor II (IGF-II) on the IGF-II/mannose-6-phosphate receptor in human breast cancer cells and possible consequences on mitogenic activity of IGF-II. Mol Endocrinol 4:1327–1335, 1990
Yee D, Paik S, Lebovic GS, Marcus RR, Favoni RE, Cullen KJ, Lippman ME, Rosen N: Analysis of IGF-I gene expression in malignancy, evidence for a paracrine role in human breast cancer. Mol Endocrinol 3:509–517, 1989
Ahmed SR, Manni A, Gray G, Hammond JM: Characterization and hormonal regulation of radioimmunoassayable IGF-I (insulin-like growth factor I) like activity and IGF-binding proteins secreted by human breast cancer cells. Anticancer Res 10:1217–1224, 1990
Daly RJ, Harris WH, Wang DY, Darbre PD: Autocrine production of insulin-like growth factor II using an inducible expression system results in reduced estrogen sensitivity of MCF-7 human breast cancer cells. Cell Growth Diff 2:457–464, 1991
Cullen KJ, Lippman ME, Chow D, Hill S, Rosen N, Zwiebel JA: Insulin-like growth factor-II expression in MCF-7 cells induces phenotypic changes associated with malignant progression. Mol Endocrinol 6:91–100, 1992
Stewart AJ, Johnson MD, May FEB, Westley BR: Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J Biol Chem 265:21172–21178, 1990
Arteaga CL, Kitten LJ, Coronado EB, Jacobs S, Kull FC Jr, Allred DC, Osborne CK: Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 84:1418–1423, 1989
Brünner N, Yee D, Kern FG, Spang-Thomsen M, Lippman ME, Cullen KJ: Effect of endocrine therapy on growth of T61 human breast cancer xenografts is directly correlated to a specific down-regulation of insulin-like growth factor-II (IGF-II). Eur J Cancer 29A:562–569, 1993
Paik S: Expression of IGF-I and IGF-II mRNA in breast tissue. Breast Cancer Res Treat 22:31–38, 1992
Jammes H, Peyrat JP, Ban E, Vilain MO, Haour F, Djiane J, Bonneterre J: Insulin-like growth factor-1 receptors in human breast tumours — localisation and quantification by histo-autoradiographic analysis. Br J Cancer 66:248–253, 1992
Bonneterre J, Peyrat JP, Beuscart R, Demaille A: Prognostic significance of insulin-like growth factor I receptors in human breast cancer. Cancer Res 50:6931–6935, 1990
Foekens JA, Portengen H, van Putten WLJ, Trapman AM, Reubi J-C, Alexieva-Figusch J, Klijn JGM: Prognostic value of receptors for insulin-like growth factor I, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res 49:7002–7009, 1989
Papa V, Gliozzo B, Clark GM, McGuire WL, Moore D, Fujita-Yamaguchi Y, Vigneri R, Goldfine ID, Pezzino V: Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res 53:3736–3740, 1993
Papa V, Hartmann KKP, Rosenthal SM, Maddux BA, Siiteri PK, Goldfine ID: Progestins induce down-regulation of insulin-like growth factor-I receptors in human breast cancer cells: potential autocrine role for IGF-II. Mol Endocrinol 5:709–717, 1991
Peyrat JP, Bonneterre J, Hecquet B, Vennin P, Louchez MM, Fournier C, Lefebvre J, Demaille A: Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer 29A:492–497, 1993
Pollak M, Costantino J, Polychronakos C, Blauer S-A, Guyda H, Redmond C, Fisher B, Margolese R: Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients. J Natl Cancer Inst 82:1693–1697, 1990
Friedl A, Jordan VC, Pollak M: Suppression of serum insulin-like growth factor-1 levels in breast cancer patients during adjuvant tamoxifen therapy. Eur J Cancer 29A:1368–1372, 1993
Torrisi R, Pensa F, Orengo MA, Catsafados E, Ponzani P, Boccardo F, Costa A, Decensi A: The synthetic retinoid fenretinide lowers plasma insulin-like growth factor-I levels in breast cancer patients. Cancer Res 53:4769–4771, 1993
Reed MJ, Christodoulides A, Koistinen R, Seppala M, Teale JD, Ghilchik MW: The effect of endocrine therapy with medroxyprogesterone acetate, 4-hydroxy-androstenedione or tamoxifen on plasma concentrations of insulin-like growth factor (IGF)-I, IGF-II and IGFBP-1 in women with advanced breast cancer. Int J Cancer 52:208–212, 1992
Clemmons DR, Camacho-Hubner C, Coronado E, Osborne CK: Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: correlation with estrogen receptor status. Endocrinol 127:2679–2686, 1990
Yee D, Favoni RE, Lippman ME, Powell DR: Identification of insulin-like growth factor binding proteins in breast cancer cells. Breast Cancer Res Treat 18:3–10, 1991
McGuire WL Jr, Jackson JG, Figueroa JA, Shimasaki S, Powell DR, Yee D: Regulation of insulin-like growth factor-binding protein (IGFBP) expression by breast cancer cells: use of IGFBP-1 as an inhibitor of insulin-like growth factor action. J Natl Cancer Inst 84:1336–1341, 1992
Fontana JA, Burrows-Mezu A, Clemmons DR, LeRoith D: Retinoid modulation of insulin-like growth factor-binding proteins and inhibition of breast carcinoma proliferation. Endocrinol 128:1115–1122, 1991
Oh YM, Muller HL, Lamson G, Rosenfeld RG: Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells — cell surface binding and growth inhibition. J Biol Chem 268:14964–14971, 1993
Oh Y, Mueller HL, Pham Y, Rosenfeld RG: Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells. J Biol Chem 268:26045–26048, 1993
Figueroa JA, Jackson JG, McGuire WL, Krywicki RF, Yee D: Expression of insulin-like growth factor binding proteins in human breast cancer correlates with estrogen receptor status. J Cell Biochem 52:196–205, 1993
Shao ZM, Sheikh MS, Ordonez JV, Feng P, Kute T, Chen JC, Aisner S, Schnaper L, LeRoith D, Roberts CT, Fontana J: IGFBP-3 gene expression and estrogen receptor status in human breast carcinoma. Cancer Res 52:5100–5103, 1992
Arteaga CL, Coronado E, Osborne CK: Blockade of the epidermal growth factor receptor inhibits transforming growth factor-α induced but not estrogen induced growth of hormone dependent human breast cancer. Mol Endocrinol 2:1064–1069, 1988
Luetteke NC, Qiu TH, Pieffer RL, Oliver P, Smithies O, Lee DC: TGF-alpha deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice. Cell 73:263–278, 1993
Busby WH Jr, Klapper DG, Clemmons DR: Purification of a 31,000-dalton insulin-like growth factor binding protein from human amniotic fluid, isolation of two forms with different biological actions. J Biol Chem 263:14203–14210, 1988
Elgin RG, Busby WH Jr, Clemmons DR: An insulin-like growth factor (IGF) binding protein enhances the biologic response to IGF-I. Proc Natl Acad Sci USA 84:3254–3258, 1987
Figueroa JA, Sharma J, Jackson JG, McDermott MJ, Hilsenbeck SG, Yee D: Recombinant insulin-like growth factor binding protein-1 inhibits IGF-I, serum, and estrogen-dependent growth of MCF-7 human breast cancer cells. J Cell Physiol 157:229–236, 1993
Yee D, Jackson JG, Kozelsky TW, Figueroa JA: Expression of insulin-like growth factor-I inhibits IGF-I mediated growth in MCF-7. Cell Growth Diff 5:73–77, 1994
Camacho-Hubner C, McCusker RH, Clemmons DR: Secretion and biological actions of insulin-like growth factor binding proteins in two human tumor-derived cell lines in vitro. J Cell Physiol 148:281–289, 1991
Yee D, Favoni RE, Lupu R, Cullen KJ, Lebovic GS, Huff KK, Lee PDK, Lee YL, Powell DR, Dickson RB, Rosen N, Lippman ME: The insulin-like growth factor binding protein BP-25 is expressed by human breast cancer cells. Biochem Biophys Res Commun 158:38–44, 1989
Young SCJ, Miles MV, Clemmons DR: Determination of the pharmacokinetic profiles of insulin-like growth factor binding protein-1 and protein-2 in rats. Endocrinol 131:1867–1873, 1992
Trojan J, Blossey BK, Johnson TR, Rudin SD, Tykocinski M, Ilan J, Ilan J: Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor-I. Proc Natl Acad Sci USA 89:4874–4878, 1992
Trojan J, Johnson TR, Rudin SD, Ilan J, Tykocinski ML, Ilan J: Treatment and prevention of rat glioblastoma by immunogenic c6 cells expressing antisense insulin-like growth factor-I RNA. Science 259:94–97, 1993
Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM: In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256:1550–1552, 1992
Berns EMJJ, Klijn JGM, van Staveren IL, Portengen H, Foekens JA: Sporadic amplification of the insulin-like growth factor I receptor gene in human breast tumors. Cancer Res 52:1036–1039, 1992
Porcu P, Ferber A, Pietrzkowski Z, Roberts CT, Adamo M, LeRoith D, Baserga R: The growth-stimulatory effect of simian virus-40 T-antigen requires the interaction of insulin-like growth factor-1 with its receptor. Mol Cell Biology 12:5069–5077, 1992
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yee, D. The insulin-like growth factor system as a target in breast cancer. Breast Cancer Res Tr 32, 85–95 (1994). https://doi.org/10.1007/BF00666209
Issue Date:
DOI: https://doi.org/10.1007/BF00666209